AAAAAA

   
Results: 1-25 | 26-30
Results: 1-25/30
CD31 mismatching affects marrow transplantation outcome
Authors: Grumet, FC Hiraki, DD Brown, BW Zehnder, JL Zacks, ES Draksharapu, A Parnes, J Negrin, RS
Citation: Fc. Grumet et al., CD31 mismatching affects marrow transplantation outcome, BIOL BLOOD, 7(9), 2001, pp. 503-512
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience
Authors: Cao, TM Horning, SF Negrin, RS Hu, WW Johnston, LF Taylor, TL Shizuru, JA Hoppe, RT Brown, BW Blume, KG Stockerl-Goldstein, K
Citation: Tm. Cao et al., High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience, BIOL BLOOD, 7(5), 2001, pp. 294-301
Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation
Authors: Alvarnas, JC Linn, YC Hope, EG Negrin, RS
Citation: Jc. Alvarnas et al., Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation, BIOL BLOOD, 7(4), 2001, pp. 216-222
Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma
Authors: Verneris, MR Ito, M Baker, E Arshi, A Negrin, RS Shizuru, JA
Citation: Mr. Verneris et al., Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma, BIOL BLOOD, 7(10), 2001, pp. 532-542
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease
Authors: Stuart, MJ Chao, NS Horning, SJ Wong, RM Negrin, RS Johnston, LJ Shizuru, JA Long, GD Blume, KG Stockerl-Goldstein, KE Goldstein, S
Citation: Mj. Stuart et al., Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease, BIOL BLOOD, 7(10), 2001, pp. 552-560
CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56(+) T cells
Authors: Lopez, RD Waller, EK Lu, PH Negrin, RS
Citation: Rd. Lopez et al., CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56(+) T cells, CANCER IMMU, 49(12), 2001, pp. 629-640
Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells
Authors: Kornacker, M Verneris, MR Kornacker, B Scheffold, C Negrin, RS
Citation: M. Kornacker et al., Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells, IMMUNOL LET, 76(3), 2001, pp. 169-173
Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis
Authors: Kornacker, M Schlattner, U Wallimann, T Verneris, MR Negrin, RS Kornacker, B Staratschek-Jox, A Diehl, V Wolf, J
Citation: M. Kornacker et al., Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis, INT J CANC, 94(4), 2001, pp. 513-519
Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+cells in patients with advanced hematologic malignancies
Authors: Cao, TM Kusnierz-Glaz, C Valone, F Stockerl-Goldstein, KE Hu, WW Johnston, L Blume, KG Strober, S Negrin, RS
Citation: Tm. Cao et al., Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+cells in patients with advanced hematologic malignancies, CANCER, 91(12), 2001, pp. 2205-2213
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial
Authors: Horning, SJ Negrin, RS Hoppe, RT Rosenberg, SA Chao, NJ Long, GD Brown, BW Blume, KG
Citation: Sj. Horning et al., High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial, BLOOD, 97(2), 2001, pp. 404-409
Expansion of cytolytic CD8(+) natural killer T cells with limited capacityfor graft-versus-host disease induction due to interferon gamma production
Authors: Baker, J Verneris, MR Ito, M Shizuru, JA Negrin, RS
Citation: J. Baker et al., Expansion of cytolytic CD8(+) natural killer T cells with limited capacityfor graft-versus-host disease induction due to interferon gamma production, BLOOD, 97(10), 2001, pp. 2923-2931
Allogeneic bone marrow transplantation for BCR-ABL positive acute lymphoblastic leukemia
Authors: Snyder, DS Nademanee, AP O'Donnell, MR Parker, PM Stein, AS Margolin, K Somlo, G Molina, A Spielberger, R Kashyap, A Fung, H Vora, N Slovak, ML Niland, J Palmer, J Negrin, RS Amylon, MD Blume, KG Forman, SJ
Citation: Ds. Snyder et al., Allogeneic bone marrow transplantation for BCR-ABL positive acute lymphoblastic leukemia, HEMAT BLOOD, 40, 2001, pp. 414-418
Use of reporter genes for optical measurements of neoplastic disease in vivo
Authors: Contag, CH Jenkins, D Contag, FR Negrin, RS
Citation: Ch. Contag et al., Use of reporter genes for optical measurements of neoplastic disease in vivo, NEOPLASIA, 2(1-2), 2000, pp. 41-52
Cellular therapy comes of age
Authors: Negrin, RS
Citation: Rs. Negrin, Cellular therapy comes of age, CYTOTHERAPY, 2(3), 2000, pp. 177-177
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic tell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma
Authors: Johnston, LJ Stockerl-Goldstein, KE Hu, WW Negrin, RS Hoppe, RT Blume, KG Horning, SJ
Citation: Lj. Johnston et al., Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic tell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma, BIOL BLOOD, 6(5A), 2000, pp. 555-562
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor"mobilization of peripheral blood progenitor cells
Authors: Stockerl-Goldstein, KE Reddy, SA Horning, SJ Blume, KG Chao, NJ Hu, WW Johnston, LJ Long, GD Strober, S Wong, RM Feiner, RH Kohler, S Negrin, RS
Citation: Ke. Stockerl-goldstein et al., Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor"mobilization of peripheral blood progenitor cells, BIOL BLOOD, 6(5), 2000, pp. 506-512
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation
Authors: Cao, TM Negrin, RS Stockerl-Goldstein, KE Johnston, LJ Shizuru, JA Taylor, TL Rizk, NW Wong, RM Blume, KG Hu, WW
Citation: Tm. Cao et al., Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation, BIOL BLOOD, 6(4), 2000, pp. 387-394
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma
Authors: Alvarnas, JC Negrin, RS Horning, SJ Hu, WW Long, GD Schriber, JR Stockerl-Goldstein, K Tierney, K Wong, R Blume, KG Chao, NJ
Citation: Jc. Alvarnas et al., High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma, BIOL BLOOD, 6(3A), 2000, pp. 352-358
Equivalence of 2 effective graft-versus-host disease prophylaxis regimens:Results of a prospective double-blind randomized trial
Authors: Chao, NJ Snyder, DS Jain, M Wong, RM Niland, JC Negrin, RS Long, GD Hu, WW Stockerl-Goldstein, KE Johnston, LJ Amylon, MD Tierney, DK O'Donnell, MR Nademanee, AP Parker, P Stein, A Molina, A Fung, H Kashyap, A Kohler, S Spielberger, R Krishnan, A Rodriguez, R Forman, SJ Blume, KG
Citation: Nj. Chao et al., Equivalence of 2 effective graft-versus-host disease prophylaxis regimens:Results of a prospective double-blind randomized trial, BIOL BLOOD, 6(3), 2000, pp. 254-261
Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer
Authors: Negrin, RS Atkinson, K Leemhuis, T Hanania, E Juttner, C Tierney, K Hu, WW Johnston, LJ Shizuru, JA Stockerl-Goldstein, KE Blume, KG Weissman, IL Bower, S Baynes, R Dansey, R Karanes, C Peters, W Klein, J
Citation: Rs. Negrin et al., Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer, BIOL BLOOD, 6(3), 2000, pp. 262-271
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy
Authors: Hu, WW Negrin, RS Stockerl-Goldstein, K Johnston, LJ Shizuru, JA Wong, RM Chao, NJ Long, GD Feiner, RH Blume, KG
Citation: Ww. Hu et al., Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy, BIOL BLOOD, 6(1), 2000, pp. 58-69
Resistance of ex vivo expanded CD3(+)CD56(+) T cells to Fas-mediated apoptosis
Authors: Verneris, MR Kornacker, M Mailander, V Negrin, RS
Citation: Mr. Verneris et al., Resistance of ex vivo expanded CD3(+)CD56(+) T cells to Fas-mediated apoptosis, CANCER IMMU, 49(6), 2000, pp. 335-345
Effect of oral glutamine supplementation during bone marrow transplantation
Authors: Dickson, TMC Wong, RM Negrin, RS Shizuru, JA Johnston, LJ Hu, WW Blume, KG Stockerl-Goldstein, KE
Citation: Tmc. Dickson et al., Effect of oral glutamine supplementation during bone marrow transplantation, J PARENT EN, 24(2), 2000, pp. 61-66
CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies
Authors: Lopez, RD Xu, S Guo, B Negrin, RS Waller, EK
Citation: Rd. Lopez et al., CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies, BLOOD, 96(12), 2000, pp. 3827-3837
A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer
Authors: Hu, WW Long, GD Stockerl-Goldstein, KE Johnston, LJ Chao, NJ Negrin, RS Blume, KG
Citation: Ww. Hu et al., A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer, CLIN CANC R, 5(11), 1999, pp. 3411-3418
Risultati: 1-25 | 26-30